Clinical Trial Update: Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure [Phase 2]

View source ↗

Summary

Phase 2 trial of NCX-1000 in patients with portal hypertension showed preliminary efficacy signals and tolerability after repeated oral dosing, but the study wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Portal Hypertension

Drugs mentioned

• NCX-1000 (NCX-1000)

Snippet

Sponsor: Forest Laboratories | Conditions: Portal Hypertension | Phase 2 | Status: TERMINATED